Group items tagged

According to Theresa Boyle, Health Report of The Star, states that scientists have discovered the process that underlies in the development of cancer cell mutations in breast cancer. Mike Stratton who is part of the International Cancer Genome Consortium at the MaRS Centre states these "findings will go a long way in helping the consortium achieve its goal of mapping the genetic mutations in 50 different types of cancer by 2018."

McGuinty and Schwarzenegger team signed a new $30M joint research venture to develop new stem cell therapies to help conquer cancer. The new Cancer Stem Cell Consortium will be headquartered at the MaRS Centre.

McGuinty and Schwarzenegger team signed a new $30M joint research venture to develop new stem cell therapies to help conquer cancer. The new Cancer Stem Cell Consortium will be headquartered at the MaRS Centre. Jun 1, 2007

Harper committed the cancer funding, starting April 1 2012, while visiting Toronto's MaRS Discovery District. The funding announced today will help doctors detect cancer sooner and give health care workers, support groups and survivors the help they need to fight back against cancer. The funding builds on the program's progress on prevention, diagnosis, treatment and hope, on a path to a cure.

The Ontario Institute for Cancer Research (OICR) is a new center of excellence. It is moving Ontario to the forefront of discovery and innovation in cancer research

The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board. Mention of Dr. Stiller Co-Founding MaRS.

The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board. Mention of Dr. Stiller Co-Founding MaRS. Jan 21, 2009

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) announced an investment of $1 million towards the development of two new promising cancer therapies. OncoTek Drug Delivery Inc (a subsidiary of Receptor Therapeutics) is one of the recipients.

Tom Hudson is announced as the President and Scientific Director of the Ontario Institute for Cancer Research (OICR).

Tom Hudson is announced as the President and Scientific Director of the Ontario Institute for Cancer Research (OICR). Nov 13, 2006

To improve early detection and treatment of cancer, a pair of Toronto scientists, Dr David Jaffray, a senior scientist in the division of biophysics and bioimaging at the Ontario Cancer Institute and Dr Christine Allen, an associate professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto has developed a technology that combines contrast agents with targeted, long-lasting nano-particles for use in multiple medical imaging platforms. MaRS Innovation (MI) and the University Health Network (UHN) have now entered into an agreement to collaboratively commercialize this promising technology. Dec 23, 2009

The Ontario Institute for Cancer Research in 2010 will grow its workforce, step up efforts to commercialize discoveries, and aim to fulfill research goals to be detailed in a second strategic plan set to be submitted next month to provincial officials, according to the institute's president and scientific director, Tom Hudson.

Calvin Stiller, chairman of the Ontario Institute for Cancer Research, won the Canada Gairdner Wightman Award for his work on the use of cyclosporine as a treatment for organ transplant rejection, but also for his role as a scientific entrepreneur, and a rainmaker for major scientific projects. Dr. Calvin Stiller is the Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada.

Toronto's medical community is buzzing about an invention that could change the way health professionals screen for infectious disease and cancer.

"Diamond Schmitt Architects will design research laboratory space for the Ontario Institute for Cancer Research (OICR) at the MaRS Phase II west tower currently under construction in downtown Toronto." MaRS Phase II occupancy is slatted for 2013.

The Ontario Institute for Cancer Research (OICR) is applying the newest concepts in life sciences-stem cell therapies, personalized medicine-to one of the oldest diseases.

Tenille Bonoguore, Globe and Mail features the MaRS Centre and meets 12 of its' "best specimens." MaRS is one of the 10 largest biomedical clusters in the continent.

Tenille Bonoguore, Globe and Mail features the MaRS Centre and meets 12 of its' "best specimens." Bonoguore states "MaRS Centre is one of the 10 largest biomedical clusters in the continent." Jan 5, 2008

InDanio, a drug-discovery company based in Toronto's MaRS Discovery District, focuses on nuclear receptors, a class of proteins that are related to some of the most \ndevastating and prevalent diseases on the planet, including immune disorders, obesity, diabetes and most cancers.

InDanio, a drug-discovery company based in Toronto's MaRS Discovery District, focuses on nuclear receptors, a class of proteins that are related to some of the most devastating and prevalent diseases on the planet, including immune disorders, obesity, diabetes and most cancers. devastating and prevalent diseases on the planet, including immune disorders, obesity, diabetes and most cancers.

Grade 12 students from St. Elizabeth Catholic High School won first place prize in the 2009 Sanofi-Aventis BioTalent Challenge (SABC) in the Greater Toronto region. These students' research demonstrated that high frequency ultrasound could be used to test the effectiveness of a cancer therapy drug by detecting cell death in leukemia cells. MaRS is one of the Regional competition sponsors.

Grade 12 students from St. Elizabeth Catholic High School won first place prize in the 2009 Sanofi-Aventis BioTalent Challenge (SABC) in the Greater Toronto region. These students' research demonstrated that high frequency ultrasound could be used to test the effectiveness of a cancer therapy drug by detecting cell death in leukemia cells. MaRS is one of the Regional competition sponsors. April 15, 2009

The 2010 Canada Gairdner Awards honour groundbreaking medical research behind cancer, epilepsy and heart disease and malaria treatments. Dr. Calvin Stiller, Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada is a recipient for the 2010 Canada Gairdner Award.

The 2010 Canada Gairdner Awards honour groundbreaking medical research behind cancer, epilepsy and heart disease and malaria treatments. Dr. Calvin Stiller, Chair of Ontario Institute for Cancer Research, Co-Founder and Board Member of MaRS Discovery District and past chair of Genome Canada is a recipient for the 2010 Canada Gairdner Award.

Profound Medical Inc, a MaRS client hopes to improve quality of life for men with prostate cancer by developing a faster, more precise treatment aimed at reducing side effects. Profound Medical won the $200,000 Premier's Catalyst Award for a start-up company with the best innovation. Avenir Medical Inc, a MaRS Client was named Ontario's Next Top Entrepreneur at the conference of the Ontario Centres of Excellence.